cmi_blog_daily_dose

  Oncology Radiopharmaceuticals Oncology Radiopharmaceuticals agents are designed to penetrate cancer cells and break down naturally once they attach to a cancer cell. The radioactive compound then decays, causing irreparable damage to the DNA of nearby cells. Cancer cells are particularly susceptible to DNA damage from radiation, and a single molecule of radiopharmaceutical can kill up to 10 cells around a bound cell. Radiation therapy is an important part of cancer treatment, with the National Cancer Institute estimating that nearly half of all cancer patients will receive some form of radiation therapy during their lifetimes. In radiation therapy, a beam of high-energy radiation is directed at the cancerous growth in order to kill it. Recently, however, oncologists have shown a growing interest in using radiopharmaceuticals, which are drugs that contain radioactive particles attached to them. These drugs can accurately target cancer cells and help treat cancer. Although these ...

  Contract Research Organization Services provide support to the pharmaceutical, medical device, and biopharmaceutical industries in the form of research services on a contract basis. These services include drug development, clinical research, preclinical research, commercialization, clinical trials management, biologic assay development, and pharmacovigilance, among others. Since contract research is done on an individual institute/factory basis instead of a large-scale corporate research budget, this enables smaller organizations to enter into the contract research industry without being too dependent upon larger pharmaceutical or biotechnology companies. Contract Research Organization Services also help keep costs down by managing the contract process as a one-time event rather than a series of projects. Contract research organizations (CROs) have become an integral part of the healthcare sector. In drug development, the safety of new medical devices or pharmaceuticals is crit...